SARS-CoV2-S Antigen Expression in Insect Cells for Rapid Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine production methods for COVID-19 and other viruses struggle to produce sufficient vaccines in a short time to immunize large populations effectively, while also facing challenges with emerging virus variants and supply chain issues.
Innovation Solution
The method involves expressing the SARS-CoV2-S Δ21 protein in eukaryotic cells without the M protein, allowing it to be densely located in the cytoplasmic membrane, and using this protein presentation in cell membranes as a novel vaccine approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional vaccine production methods are used, then vaccine safety and immunogenicity are maintained, but production time is extended beyond 10 years and large-scale production capacity is insufficient
Solution Approach 1:
The invention segments the S protein into functional domains (S1 with RBD and S2 with fusion peptide and HR1/HR2) and expresses them separately in insect cells using baculovirus vectors. This segmentation allows parallel production of multiple antigen components, significantly accelerating vaccine development while maintaining immunogenicity through preservation of critical functional domains.
Solution Approach 2:
The invention uses insect cell-baculovirus expression systems as an intermediary platform to produce viral antigens. This intermediary system enables rapid antigen production without requiring complete virus cultivation, thereby reducing development time from over 10 years to a much shorter period while maintaining large-scale production capacity.
2Reliability
If whole inactivated virus vaccines are produced, then comprehensive immune coverage is achieved, but production complexity and time requirements increase significantly
Solution Approach 1:
The invention extracts only the essential immunogenic components (S1 and S2 protein domains) from the complete virus structure and expresses them recombinantly in insect cells. This extraction eliminates the need for complex whole virus inactivation processes while preserving the critical antigenic determinants that elicit protective immune responses.
Solution Approach 2:
The invention applies local quality by expressing specific functional domains of the S protein (such as RBD in S1 and fusion peptide/HR1 in S2) at high levels in insect cells. This localized expression of critical immunogenic regions simplifies production compared to whole virus methods while maintaining effective immune coverage through targeted antigen presentation.
3Productivity
If rapid vaccine production is implemented to address emerging variants, then production speed increases, but manufacturing precision and antigen quality control may be compromised
Solution Approach 1:
The invention performs preliminary action by designing and validating insect cell-baculovirus expression systems before outbreak scenarios occur. The system is pre-optimized to produce high-quality viral antigens with correct folding and post-translational modifications, ensuring that when rapid production is needed, manufacturing precision is maintained while achieving high productivity through established protocols.
Data Source
AI summary
The invention is based on the deletion of 21 amino acids from the C-terminal region of the S2 subunit of SARS-CoV2-S protein and transporting the Si subunit, which is fused to S2 to the cell membranes. In this way, the presentation of the antigenic S1 subunit of SARS-CoV2-S protein in large amounts and in its natural structure in the cell membrane and its use as a whole cell or cell membrane has been determined as a new vaccination protocol for the SARS-CoV-2. Designing the S2 subunit of SARS-CoV2-S protein as a carrier, fusing any bacterial, viral, and tumor proteins with antigenic properties and transporting it to the cell membrane will be a comprehensive vaccination protocol that will cover all bacteria, viruses and even tumors.